Stock Price, News, Quote and Profile of MOONLAKE IMMUNOTHERAPEUTICS(NASDAQ:MLTX) stock

MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ:MLTX (12/20/2024, 4:30:01 PM)

After market: 52.17 0 (0%)

52.17

+0.29 (+0.56%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-211.11%

Sales Q2Q%N/A

CRS26.6

6 Month35.75%

Overview

Earnings (Last)11-07 2024-11-07/bmo

Earnings (Next)N/A N/A

Ins Owners12.86%

Inst Owners97.39%

Market Cap3.33B

Shares63.91M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts84.35

Short Float %14.91%

Short Ratio34.49

IPO10-20 2020-10-20

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 50 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Company Info

MOONLAKE IMMUNOTHERAPEUTICS

Dorfstrasse 29

Zug ZUG

P: 41415108022

Employees: 50

Website: https://moonlaketx.com/

MLTX News

2 months ago - Market News VideoMLTX Makes Notable Cross Below Critical Moving Average

2 months ago - Market News VideoMoonLake Immunotherapeutics (MLTX) Shares Cross Below 200 DMA

3 months ago - MoonLake Immunotherapeutics AGMoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics...

5 months ago - Market News VideoBullish Two Hundred Day Moving Average Cross - MLTX

6 months ago - MoonLake Immunotherapeutics AGMoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

7 months ago - MoonLake Immunotherapeutics AGMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MOONLAKE IMMUNOTHERAPEUTICS (MLTX)

Nasdaq Stock Screener

USA Stock Screener